Prothena:A Phase 3, Randomized, Multicenter, Double-Blind,Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosi

Clinical Trial Grant

Duke Scholars

Principal Investigator Cristiana A. Costa Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Prothena Biosciences Limited

Start Date

February 24, 2022

End Date

February 28, 2027

Administered By

Duke Cancer Institute

Awarded By

Prothena Biosciences Limited

Start Date

February 24, 2022

End Date

February 28, 2027